Version July 2025
This algorithm describes management of higher-risk primary myelofibrosis and secondary myelofibrosis. None of the available drugs has disease-modifying activity; participation in a clinical trial is encouraged for both symptomatic and asymptomatic patients.
Refer to related UpToDate material for details of diagnosis, risk stratification, fitness for HCT, and treatment.ESA: erythropoiesis-stimulating agent; HCT: hematopoietic cell transplantation; RBC: red blood cell.
* RBC transfusions should be given as needed for relief of anemia-related symptoms during treatment.